Molecular structure of Albaconazole, CAS Number: 187949-02-6
Albaconazole (CAS 187949-02-6)
Application:
Albaconazole is an antifungal agent
CAS Number:
187949-02-6
Molecular Weight:
431.83
Molecular Formula:
C20H16ClF2N5O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Albaconazole is a broad-spectrum antifungal agent that inhibits the synthesis of ergosterol, a component of fungal cell membranes. It functions by targeting and inhibiting the enzyme lanosterol 14-alpha-demethylase. This disruption of ergosterol biosynthesis leads to the accumulation of toxic methylated sterol intermediates, causing membrane dysfunction and ultimately leading to fungal cell death. Albaconazole′s mechanism of action involves binding to the active site of lanosterol 14-alpha-demethylase, thereby preventing the enzyme from catalyzing the demethylation reaction. This interference with ergosterol production disrupts the integrity and function of the fungal cell membrane, resulting in the inhibition of fungal growth and proliferation.
Albaconazole (CAS 187949-02-6) References
- Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits. | Capilla, J., et al. 2003. Antimicrob Agents Chemother. 47: 1948-51. PMID: 12760872
- In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. | Miller, JL., et al. 2004. Antimicrob Agents Chemother. 48: 384-7. PMID: 14742184
- Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. | Guedes, PM., et al. 2004. Antimicrob Agents Chemother. 48: 4286-92. PMID: 15504854
- Emerging azole antifungals. | Chen, A. and Sobel, JD. 2005. Expert Opin Emerg Drugs. 10: 21-33. PMID: 15757401
- Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. | Morera-López, Y., et al. 2005. Med Mycol. 43: 505-10. PMID: 16320494
- New and emerging treatments for fungal infections. | Pasqualotto, AC. and Denning, DW. 2008. J Antimicrob Chemother. 61 Suppl 1: i19-30. PMID: 18063600
- [Identification and susceptibility against fluconazole and albaconazole of 100 yeasts' strains isolated from vaginal discharge]. | Arechavala, AI., et al. 2007. Rev Iberoam Micol. 24: 305-8. PMID: 18095765
- Efficacy of albaconazole against Candida albicans in a vaginitis model. | González, GM., et al. 2009. Antimicrob Agents Chemother. 53: 4540-1. PMID: 19635949
- New generation azole antifungals in clinical investigation. | Girmenia, C. 2009. Expert Opin Investig Drugs. 18: 1279-95. PMID: 19678798
- Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. | Pasqualotto, AC., et al. 2010. Curr Opin Investig Drugs. 11: 165-74. PMID: 20112166
- Newer antifungal agents. | Türel, O. 2011. Expert Rev Anti Infect Ther. 9: 325-38. PMID: 21417872
- A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation. | van Rossem, K. and Lowe, JA. 2013. Clin Pharmacol. 5: 23-31. PMID: 23390369
- Discovery of a novel broad-spectrum antifungal agent derived from albaconazole. | Guillon, R., et al. 2013. ACS Med Chem Lett. 4: 288-92. PMID: 24900660
- A randomized, double-blind, multiple-dose, placebo-controlled, dose escalation study with a 3-cohort parallel group design to investigate the tolerability and pharmacokinetics of albaconazole in healthy subjects. | Dietz, AJ., et al. 2014. Clin Pharmacol Drug Dev. 3: 25-33. PMID: 27128227
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Albaconazole, 2.5 mg | sc-210770 | 2.5 mg | $311.00 |